Alle Fälle anzeigen
UPC APP 8339/2025
—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Beklagte
- Amgen Technology (Ireland) Unlimited Company
- Amgen N.V.
- Amgen GmbH (DE)
- Amgen GmbH (AT)
- Amgen AB
- Amgen S.A.S.
- Amgen s.r.l.
- Amgen Biofarmacêutica Lda.
- Amgen Zdravila D.O.O.
Vertreter: Tilman Müller-Stoy (Bardehle Pagenberg) - Division
- Court of Appeal
- Richter
- —
- Technology
- Organic Chemistry
- Sprache
- —
- Erste Entscheidung
- 19. Juni 2025
Entscheidungen
- 2025-06-19BerufungsentscheidungGeneric application
The Court of Appeal set out general principles for rehearing applications under Art. 81(1)(b) UPCA, establishing that only fundamental procedural defects that would have led to a different outcome can justify rehearing, in proceedings where Alexion sought to reopen a dismissed provisional measures appeal against Amgen concerning EP 3 167 888.
Rechtsfragen:Rehearing application (Art. 81(1) UPCA, R. 245 RoP)Fundamental procedural defectStandard for reopening final decisions
Dokumente
- 2AFD646F74F626C4549F4F2CC557128E_en.pdf2025-06-19EN